State Board of Administration of Florida Retirement System Purchases 1,320 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

State Board of Administration of Florida Retirement System raised its position in Revolution Medicines, Inc. (NASDAQ:RVMDGet Rating) by 7.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 19,855 shares of the company’s stock after buying an additional 1,320 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Revolution Medicines were worth $387,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its holdings in Revolution Medicines by 53.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,150 shares of the company’s stock valued at $42,000 after buying an additional 750 shares during the period. Ensign Peak Advisors Inc increased its holdings in Revolution Medicines by 7.5% in the 1st quarter. Ensign Peak Advisors Inc now owns 11,990 shares of the company’s stock valued at $306,000 after buying an additional 840 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in Revolution Medicines by 10.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 23,800 shares of the company’s stock valued at $609,000 after buying an additional 2,200 shares during the period. SG Americas Securities LLC increased its holdings in Revolution Medicines by 48.0% in the 1st quarter. SG Americas Securities LLC now owns 6,942 shares of the company’s stock valued at $177,000 after buying an additional 2,251 shares during the period. Finally, Goodman Advisory Group LLC bought a new position in Revolution Medicines in the 2nd quarter valued at about $54,000. 86.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. SVB Leerink reduced their price target on shares of Revolution Medicines from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 10th. HC Wainwright reduced their price target on shares of Revolution Medicines from $37.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, November 8th. Finally, Oppenheimer assumed coverage on shares of Revolution Medicines in a research note on Thursday, October 20th. They issued an “outperform” rating and a $30.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of “Moderate Buy” and an average target price of $28.00.

Insider Buying and Selling

In related news, COO Margaret A. Horn sold 17,767 shares of Revolution Medicines stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $20.41, for a total transaction of $362,624.47. Following the sale, the chief operating officer now directly owns 17,767 shares in the company, valued at approximately $362,624.47. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, COO Margaret A. Horn sold 17,767 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $20.41, for a total value of $362,624.47. Following the transaction, the chief operating officer now owns 17,767 shares in the company, valued at approximately $362,624.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Margaret A. Horn sold 17,768 shares of the business’s stock in a transaction that occurred on Wednesday, October 26th. The stock was sold at an average price of $20.15, for a total transaction of $358,025.20. Following the completion of the transaction, the insider now owns 35,534 shares in the company, valued at approximately $716,010.10. The disclosure for this sale can be found here. Insiders have sold a total of 36,719 shares of company stock worth $743,193 in the last ninety days. Company insiders own 18.80% of the company’s stock.

Revolution Medicines Trading Down 0.4 %

RVMD opened at $20.41 on Monday. The company’s 50 day moving average is $19.64 and its 200-day moving average is $20.02. Revolution Medicines, Inc. has a 1-year low of $14.08 and a 1-year high of $30.50. The company has a market cap of $1.81 billion, a P/E ratio of -6.42 and a beta of 1.52.

Revolution Medicines (NASDAQ:RVMDGet Rating) last posted its earnings results on Monday, November 7th. The company reported ($0.87) EPS for the quarter, hitting the consensus estimate of ($0.87). Revolution Medicines had a negative net margin of 829.80% and a negative return on equity of 41.97%. The business had revenue of $3.36 million for the quarter, compared to the consensus estimate of $8.57 million. On average, equities analysts forecast that Revolution Medicines, Inc. will post -3.33 EPS for the current year.

Revolution Medicines Profile

(Get Rating)

Revolution Medicines, Inc, a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors.

Recommended Stories

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMDGet Rating).

Institutional Ownership by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.